AstraZeneca’s AZD5462 Shows Early Heart-Failure Signals in Phase IIb LUMINARA Trial

AstraZeneca’s experimental heart-failure drug AZD5462 produced encouraging cardiovascular signals in the Phase IIb LUMINARA trial, but the study did not establish that the medicine reduces hospitalizations, deaths or other major clinical outcomes. The clearest cardiac-function signal in patients with markedly reduced ejection fraction appeared at the lowest tested dose, while all three doses lowered vascular resistance in a second cohort.

The 24-week study enrolled 375 patients with chronic heart failure who were already receiving stable, maximally tolerated standard-of-care therapy. Researchers split participants into two cohorts based on left ventricular ejection fraction, or LVEF, and randomized them to placebo or once-daily AZD5462 at 20 mg, 80 mg or 360 mg. The trial was designed as a dose-ranging study to assess efficacy, safety and pharmacokinetics rather than as a definitive outcomes trial.

Results were presented on August 30 in a Hot Line session at ESC Congress 2026 and published simultaneously in Circulation. The European Society of Cardiology’s official release said the study was conducted at 69 sites in 10 countries and was funded by AstraZeneca. The U.S. ClinicalTrials.gov record lists LUMINARA as a completed Phase IIb study sponsored by AstraZeneca.

Lowest dose produced the clearest cardiac-function signal

The first cohort included 235 patients with LVEF of 35% or less, a group with substantially reduced pumping function. Its primary endpoint was the change in end-systolic volume index, or ESVI, from baseline to week 24. ESVI measures the amount of blood left in the left ventricle after contraction, adjusted for body size, and can be used to track cardiac remodeling.

At 20 mg, AZD5462 decreased ESVI by 5.4 milliliters per square meter from baseline at 24 weeks, with a p-value of 0.054 versus placebo. Secondary echocardiographic measures, including the change in LVEF, also showed their largest effects at the 20 mg dose, according to the ESC release. The result points to potential biological activity, but the p-value sits just above the commonly used 0.05 threshold. That makes it more appropriate to describe the primary-endpoint result as an early signal rather than as a statistically conclusive improvement.

The dose pattern is also important for development. A higher dose did not produce a stronger cardiac-function effect in this cohort. For a Phase II dose-ranging program, that kind of result can influence which dose moves forward, how investigators balance efficacy against tolerability and which endpoints are emphasized in a larger study. The disclosed LUMINARA data do not by themselves establish the optimal dose, but they give AstraZeneca more information for the next stage of trial design.

All three doses lowered vascular resistance in the second cohort

The second cohort included 140 patients with LVEF between 41% and 55%. Its primary endpoint was the change in systemic vascular resistance index, or SVRI, after 24 weeks. That measure reflects the resistance against which the heart pumps and is closely tied to the mechanism AstraZeneca is testing with AZD5462.

AZD5462 reduced SVRI by 19% at 20 mg, 21% at 80 mg and 15% at 360 mg. All three comparisons had p-values of 0.021 or lower, the ESC said. Those findings support the idea that the drug is engaging its intended pathway and producing a vasodilatory effect across the tested dose range.

AZD5462 is an oral small-molecule agonist of relaxin family peptide receptor 1, or RXFP1. Relaxin signaling has drawn interest in heart failure because of its effects on blood vessels, afterload and cardiorenal physiology. Earlier attempts to develop relaxin-based therapies faced challenges, including side effects that investigators have linked in part to high or supraphysiological exposure. LUMINARA was intended to test whether an oral RXFP1 agonist could produce useful cardiovascular effects while maintaining an acceptable safety profile.

The safety findings were favorable enough to support further study. The ESC reported a low incidence of adverse events and no evidence of an excess among patients receiving AZD5462. Mild blood-pressure reductions occurred, but significant hypotension was no more frequent with the drug than with placebo. Investigators also reported no evidence of the substantial volume overload seen previously with higher doses of relaxin-like drugs.

The readout supports further testing, not a late-stage conclusion

For investors, the LUMINARA readout is best viewed as a development checkpoint rather than proof of a new heart-failure therapy. The study measured cardiac remodeling and vascular resistance over 24 weeks. It was not designed to show whether AZD5462 reduces cardiovascular death, heart-failure hospitalization or another hard clinical outcome, and the investigators explicitly called for larger randomized trials focused on outcomes.

AstraZeneca’s pipeline listed AZD5462 as a Phase II heart-failure asset as of July 27, 2026. The company had not, in the official sources reviewed for this story, announced a Phase III design, enrollment target or start date tied to the LUMINARA results. That leaves several important questions open, including which patient population AstraZeneca would prioritize, what dose it would select and which clinical endpoint would anchor a larger trial.

The results nevertheless add evidence that the program is producing measurable cardiovascular effects on top of contemporary heart-failure therapy. In the lower-LVEF cohort, the most encouraging signal came from the 20 mg dose and remained just outside the conventional significance threshold for the primary endpoint. In the higher-LVEF cohort, the reduction in vascular resistance was seen across all three doses. Together with the reported tolerability profile, those findings provide a rationale for further development without resolving whether the drug will ultimately improve outcomes that matter most to patients.

The next meaningful milestone is therefore not another mechanistic interpretation of the Phase II data, but AstraZeneca’s decision on a larger outcomes-focused program. Until that happens, AZD5462 remains an experimental Phase II asset with an encouraging but still preliminary heart-failure signal.